Economic Atlas
Companies/iBio, Inc.
Company profile

iBio, Inc.

NASDAQ: IBIO · Healthcare · Biotechnology
PublicHQ Bryan, TX · BrazosCIK 0001420720Reports USD
#947 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
49D
Revenue TTM
$300.0k
Rev growth YoY (TTM)
-20.0%
Net income (FY)
-$18.4M
Employees
20
as of 2026-08-20
Market cap
$23.5M
as of 2026-08-20

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$400.0k$400.0k2025
Net income-$18.4M-$18.4M2025
Operating income-$18.6M-$18.6M2025
Total assets$23.2M$23.2M2025
Liabilities$8.3M$8.3M2025
Equity$14.9M$14.9M2025

Revenue trend

FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY24
FY24
FY25

Revenue by segment

Filed disclosures · FY2021
By product
Ibio Cdmo54%
Ibio Inc46%
By geography

Not disclosed.

The read

What is iBio, Inc.’s revenue?

iBio, Inc. booked $400.0k in FY2025 revenue, growing 78% year over year — faster than most Healthcare companies we track, at a -4594.3% net margin.

Peers · Healthcare
Amarantus BioScience Holdings, Inc.——MediciNova, Inc.41DCartesian Therapeutics, Inc.40DNeurogenesis, Inc.——Lyra Therapeutics, Inc.30DOMID Holdings, Inc.48D
Key facts
CEOMartin Brenner
SectorHealthcare
IndustryBiotechnology
HeadquartersBryan, TX
ExchangeNASDAQ: IBIO
Employees20
IPO date2008-08-19
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.